



PRESS RELEASE

Active Biotech advances ANYARA into Phase III clinical trial

Lund, Sweden, May 13, 2008 - An interim analysis has been performed in Active Biotech AB's (OMX Nordic: ACTI) ongoing Phase II/III clinical study of **ANYARA**, in patients with advanced renal cell cancer.

This analysis was performed earlier than originally planned due to a faster patient recruitment than anticipated. To date approximately 250 patients have been recruited into the study.

The study protocol has recently been reviewed in a protocol assistance procedure by EMEA and the primary as well as all secondary endpoints were endorsed.

In this interim analysis safety, efficacy, as well as certain biomarkers were evaluated in approximately 200 patients. No safety concerns significantly affecting the risk/benefit ratio for **ANYARA** were identified.

Based on the study data, Active Biotech has decided to proceed, in accordance with the study protocol, into the pivotal Phase III stage of the study to further evaluate the effect of **ANYARA** for treatment of renal cell carcinoma. The study will enroll approximately 500 patients to evaluate the anti-tumor effect of **ANYARA** in combination with interferon-alpha, compared to interferon-alpha alone. The primary endpoint is overall survival.

“This is a very important milestone for ANYARA. The results from this controlled trial support the further development in the continued Phase III part of the study”, says Sven Andréasson, CEO Active Biotech “.

After consultation with the regulatory authorities, Active Biotech will follow advice given and not publish any further details pertaining to the performed interim analysis. This decision is made in order not to compromise enrollment and integrity of the ongoing trial.

Lund, May 13, 2008
Active Biotech AB (publ)

Sven Andréasson
President and CEO

For further information, please contact:

Göran Forsberg
VP Communication & Business Development
Tel +46 (0)46-19 11 54
goran.forsberg@activebiotech.com



Notes to editors

About Renal Cell Carcinoma

Renal Cell Carcinoma affects approximately 36,000 people annually in the US and about 200,000 people worldwide. Half of patients are affected by metastases. If the disease has metastasized, average survival is one year. The survival rate of patients diagnosed with renal cancer is only 5-10% after five years (Cowen & Co, Therapeutic Categories Outlook, October 2007).

About ANYARA

In Active Biotech's ANYARA project, a drug for use in cancer targeted therapy, primarily for the treatment of renal cell carcinoma, is developed. The ongoing Phase II/III clinical study is a randomized study of ANYARA in combination with interferon-alpha (IFN- α), compared with only IFN- α , in patients locally advanced or metastatic renal cell carcinoma (RCC).

In July 2007, ANYARA was granted Orphan Drug Status by the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA). Orphan Drug designation provides a variety of incentives, including market exclusivity for up to 10 years following approval.

About Active Biotech

Active Biotech AB (OMX Nordic: ACTI) is a biotechnology company focusing on research and development of pharmaceuticals. Active Biotech has a strong R&D portfolio with pipeline products focused on autoimmune/inflammatory diseases and cancer. The most advanced projects are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, as well as ANYARA for use in cancer targeted therapy, primarily renal cell cancer. Further key projects in clinical development comprise the three orally administered compounds TASQ for prostate cancer, 57-57 for SLE and RhuDex[®] for RA.

Active Biotech AB
P.O. Box 724,
SE-220 07 Lund,
Sweden
Tel: +46 (0)46-19 20 00
Fax: +46 (0)46-19 20 50

Active Biotech is required under the Securities Markets Act to make the information in this press release public. The information was submitted for publication at 08.30 a.m. CET on May 13, 2008.